Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection

Liver Transplantation

Volumn 13, Issue 10, 2007, Pages 1396-1400

  Rodriguez, John ^a,b   Casper, Katherine ^b   Smallwood, Gregory ^c   Stieber, Andrei ^a   Fasola, Carlos ^a,b   Lehneman, Jennifer ^c   Heffron, Thomas ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Children's Healthcare of Atlanta   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD SAMPLING; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GRAFT RECIPIENT; HUMAN; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT INFECTION; REPERFUSION INJURY; SUPERINFECTION; VIRUS ISOLATION; VIRUS STRAIN; WILD TYPE;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FATAL OUTCOME; FOLLOW-UP STUDIES; FOSCARNET; GANCICLOVIR; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 35448991613     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21245     Document Type: Article

References (20)

1. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13:83-121.
2. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006;35:474-478.
3. Oldakowska-Jedynak U, Niewczas M, Ziolkowski J, Mucha K, Foroncewicz B, Bartlomiejczyk I, et al. Cytomegalovirus infection as a common complication following liver transplantation. Transplant Proc 2003;35:2295-2298.
4. Limaye A. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002;35:866-873.
5. Griffiths P, Whitley R. The challenge of CMV infection and disease in transplantation. Paper presented at: IHMF Management Strategies Workshop and 8th Annual Meeting of the IHMF; June 2000; Seattle, WA.
6. Razonable R. Management of CMV infection and disease in transplant patients. Herpes 2004;11:77-87.
7. DeClercq E. Antiviral drugs: current state of the art. J Clin Virol 2001;22:73-89.
8. Jabs DA, Martin B, Forman MS, Dunn JP, Davis JL, Weinberg DV, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001; 183:333-337.
9. Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576-583.
10. Chou S, Guentzel S, Michaels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-242.
11. Chou S, Lurain N, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188:32-39.
12. Ye LB, Huang E. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J Virol 1996;67:6339-6347.
13. Lurain NS, Bhorade SM, Pursell KJ, Avery RK, Yeldandi VV, Isada CM, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002;186:760-768,
14. Chou S, Van Wechel L, Lichy H, Marousek G. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005;49:2710-2716.
15. Chou S, Waldemer R, Senters A, Michels K, Kemble G, Miner R, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002;185:162-169.
16. Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS, and the Adult AIDS Clinical Trials Group CMV Laboratories. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotype diagnosis of antiviral drug resistance. Antimicrob Agents Chemother 1999:43:1500-1502.
17. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induces UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 2004;74:85-93.
18. Fillet AM, Auray L, Alain S, Gourlain K, Imbert BM, Najioullah F, et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother 2004;48:1865-1868.
19. Chilar T, Fuller M, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998;72:5927-5936.
20. Emery VC, Griffiths P. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci 2000;97:8039-8044.